High Body-Mass Index (Obesity)

High Body-Mass Index (Obesity) is one of the modifiable risk factors tracked by the IHME Global Burden of Disease Study. The attributable deaths shown here represent the estimated number of deaths that could be prevented if exposure to this risk factor were eliminated or reduced to optimal levels. Understanding risk factor contributions helps prioritize public health interventions and policy decisions.

Risk factor attribution uses comparative risk assessment methodology. A single death may be partially attributed to multiple risk factors, so attributable death counts should not be summed across risk factors. Data covers 204 countries from 1990 to the latest available year.

High body-mass index (BMI) — encompassing overweight (BMI 25-29.9) and obesity (BMI 30+) — is a leading metabolic risk factor, contributing to approximately 5 million deaths annually from ischaemic heart disease, stroke, type 2 diabetes, chronic kidney disease, and at least 13 types of cancer. As of 2016, WHO estimated 1.9 billion adults were overweight and 650 million were obese, with numbers continuing to rise. Childhood obesity is rising steeply, with 39 million children under five affected. The Pacific Islands, Middle East, North Africa, and the Americas have the highest prevalence. Obesity has tripled since 1975 worldwide, driven by calorie-dense processed food availability, sugar-sweetened beverages, reduced physical activity, and obesogenic urban environments. Obesity amplifies nearly every major non-communicable disease risk and shortens life expectancy by 5-14 years in severe cases. The economic cost of obesity — including healthcare, lost productivity, and disability — is estimated at $2 trillion annually.

High Body-Mass Index (Obesity) contributes to mortality from ischaemic heart disease, stroke, type 2 diabetes, chronic kidney disease, and 2 other conditions. The magnitude of impact varies by country depending on exposure levels, population demographics, and the availability of preventive and treatment services.

Population-level strategies include sugar-sweetened beverage taxation, front-of-pack nutrition labelling, restrictions on marketing unhealthy foods to children, school-based nutrition and physical activity programmes, and urban design promoting active transport. Clinical management ranges from lifestyle modification and pharmacotherapy (GLP-1 receptor agonists show significant efficacy) to bariatric surgery for severe obesity. Workplace wellness programmes, community-based physical activity initiatives, and reformulation of processed foods complement individual approaches.